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Abstract
Background: Neurodegenerative metabolic disorders such as mucopolysaccharidosis IIIB (MPSIIIB or Sanfilippo disease)
accumulate undegraded substrates in the brain and are often unresponsive to enzyme replacement treatments due to the
impermeability of the blood brain barrier to enzyme. MPSIIIB is characterised by behavioural difficulties, cognitive and later
motor decline, with death in the second decade of life. Most of these neurodegenerative lysosomal storage diseases lack
effective treatments. We recently described significant reductions of accumulated heparan sulphate substrate in liver of a
mouse model of MPSIIIB using the tyrosine kinase inhibitor genistein.
Methodology/Principal Findings: We report here that high doses of genistein aglycone, given continuously over a 9 month
period to MPSIIIB mice, significantly reduce lysosomal storage, heparan sulphate substrate and neuroinflammation in the
cerebral cortex and hippocampus, resulting in correction of the behavioural defects observed. Improvements in synaptic
vesicle protein expression and secondary storage in the cerebral cortex were also observed.
Conclusions/Significance: Genistein may prove useful as a substrate reduction agent to delay clinical onset of MPSIIIB and,
due to its multimodal action, may provide a treatment adjunct for several other neurodegenerative metabolic diseases.
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Introduction
There are over 50 described lysosomal storage disorders (LSDs),
affecting approximately 1/7000 live births [1]. Many of these are
caused by defects in lysosomal enzyme function, leading to the
accumulation of uncatabolised substrates, often resulting in
progressive neurodegeneration, neuroinflammation and death in
childhood [2]. Enzyme replacement therapies are limited to
attenuated LSDs or those affecting visceral organs alone due to an
inability of lysosomal enzymes to traffic across the adult blood
brain barrier [3]. Haematopoietic stem cell transplantation is an
efficient treatment for a very small subset of these disorders [4],
but substrate reduction therapy (SRT) which relies on inhibition of
substrate anabolism, or substrate clearance via alternative
catabolic pathways, is emerging as an effective alternative for
some glycosphingolipid LSDs [5]. SRTs are limited by the lack of
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14192agents able to effectively reduce substrate without significant toxic
side effects.
The tyrosine kinase inhibitor genistein aglycone [6] reduces
glycosaminoglycan (GAG) substrate accumulation in fibroblasts of
several mucopolysaccharide LSDs [7] has low oral toxicity in
mammals [8,9] and around 10% blood brain barrier permeability
[10]. Genistein in a supplement form has been given to patients
with MPSIIIA and IIIB, GAG storing LSDs with no effective
treatments [11], at 5 mg/kg/day, but efficacy, although encour-
aging, remains unclear [12]. We have recently shown that short-
term administration of genistein significantly reduces liver
lysosomal storage in mice with MPSIIIB [13]. Genistein has also
been shown to inhibit lipopolysaccharide (LPS) induced TNF-
alpha, IL1-alpha and IL6 production in mixed glial and astrocytic
cultures [14] and inhibit microglial activation in mixed neuron-
glial and microglial enriched cultures [15], suggesting a possible
role in attenuating neuroinflammation. We tested the hypothesis
that high doses of genistein given long-term could reduce brain
storage of primary GAG substrates, secondary glycosphingolipids
and reduce neuroinflammation, a common feature of many
neurodegenerative diseases.
Results
Genistein reduces lysosomal size and storage of heparan
sulphate in brain and liver
MPSIIIB and control wild-type (WT) mice of both sexes were
treated from 8 weeks of age for 9 months with a soy free diet or
diet containing 160 mg/kg/day of genistein aglycone. Four
coronal sections from each brain were stained and two fields of
view for each section quantified (Figure 1A). Cells throughout the
brains of MPSIIIB mice have an enlarged lysosomal compartment
size as measured by the intensity of LAMP2 (lysosomal associated
membrane protein 2) staining [16], and increased storage of the
GAG, heparan sulphate. Following genistein treatment, highly
significant 31% reductions in LAMP2 staining were observed in
the cortex (Figure 1B,C,F), 34% in the hippocampus (Figure 1D)
as well as a significant 37% reduction in the pathogenic heparan
sulphate stored in the brains of MPSIIIB mice (Figure 1E). No
changes in LAMP2 or heparan sulphate were seen in WT mice.
LAMP2 staining and total GAGs were also significantly reduced
by 64% and 35% respectively in the livers of MPSIIIB mice
receiving genistein (Figure 1G,H), whilst genistein treated WT
mice showed significantly decreased liver GAGs (Figure 1H).
Genistein reduces neuroinflammation in MPSIIIB mice
To determine if genistein could reduce neuroinflammation in
MPSIIIB, we counted the number of GFAP-positive astrocytes
(Figure 2A,B) and Isolectin B4-positive microglial cells
(Figure 2C,D) in the cerebral cortex. MPSIIIB mice exhibit a
marked increase in neuroinflammatory astrocytes and microglial
cells [13,16] concomitant with activation of several neuroinflam-
matory mediators [17,18,19] compared to WTs. Genistein
significantly reduced both GFAP-positive astrocytes (12%) and
Isolectin B4-positive microglial cells (19%) in the cerebral cortex of
MPSIIIB mice whilst no change was seen in WT mice (Figure 2A–
D). Furthermore, some microglia in the genistein treated MPSIIIB
mice appear to be smaller and less intensely stained suggesting that
they are less activated than microglia in untreated MPSIIIB mice.
Genistein may reduce secondary metabolites and
improves synaptic function
In many LSDs, including MPSIIIB, secondary metabolites such
as GM2 and GM3 gangliosides, as well as cholesterol, are
accumulated [20,21] as a result of the primary catabolic block.
Immunohistochemistry showed significant GM2 ganglioside stor-
age, particularlyin layerII,IIIand V of the cortexin MPSIIIB mice
that was significantly reduced by genistein (25%) (Figure 3A,B). In
WT mice, GM2 was virtually undetectable in the cortex as
previously shown [20]. The proportion of GM2 and GM3
measured biochemically and expressed as percentage of total
gangliosides also showed clear pathologic elevation in untreated
MPSIIIB mice (Figure 3C). However a minor reduction of GM2
was only observed in genistein treated MPSIIIB female mice (6.2%
vs 7.460.5%) while GM3 remained unchanged in all mutants
(12.560.1%). Because pooled brain sections were used for analysis,
we cannot be confident that this small GM2 reduction is mediated
by genistein. Histology reflects cerebral cortical GM2 between 0.26
to 21.94 mm relative to bregma, whilst biochemistry reflects
ganglioside storage from 22.5 to 24.5 mm relative to bregma.
We observed a significant reduction of the pre-synaptic vesicle
associated membrane protein, VAMP2 in the cerebral cortex
(Figure 3D,E) and hippocampus (not shown) of MPSIIIB mice in
agreement with our previous findings [16]. VAMP2 is part of the
SNAP/SNARE complex involved in synaptic transmission, the
loss of which has been shown to result in a dramatic reduction in
synaptic function [22]. Genistein significantly improved VAMP2
staining in cortex but not in hippocampus of MPSIIIB mice.
Genistein corrects behaviour of MPSIIIB mice
Locomotor activity, anxiety and exploratory behaviour were
monitored automatically in the open field test [23] over a 1 hour
period, as well as frequency and duration of very rapid exploratory
behaviour (speed.90 mm/s) and immobility (speed,0.05 mm/s)
at 8 months of age. MPSIIIB mice showed a highly significant
increase in the frequency with which they cross into or out of a
central area (Figure 4A), their speed in this area or the side area
(Figure 4B,C), the total distance travelled (Figure 4D), and
frequency and duration of travelling at more than 90 mm/s
(Figure 4E,F), indicating increased exploration. All of these
parameters were fully normalised by genistein treatment. MPSIIIB
mice showed significantly reduced frequency (Figure 4G) and
duration of immobility (Figure 4H) which were also normalised by
genistein treatment.
Significant gender*genotype effects were observed in centre and
side speed, distance travelled, frequency of speed over 90 mm/s,
immobility frequency and duration. Untreated female MPSIIIB
mice performed significantly worse than male MPSIIIB mice on
these tasks, however when genders were analysed separately,
significant correction of MPSIIIB mice by genistein was observed
in all cases except total distance travelled (p=0.06) and frequency
of immobility (p=0.07) for untreated vs treated male MPSIIIB
mice.
The hanging bar test measures motor co-ordination and has an
element of memory and learning due to a training period [24].
MPSIIIB mice performed significantly worse than WT mice at 10
months (Figure 4I). In contrast, genistein treated MPSIIIB mice
were completely corrected at 10 months and could not be
distinguished from WT mice suggesting retention of motor
function.
Discussion
We have shown a significant reduction in lysosomal size in the
cerebral cortex and hippocampus and in total brain storage of
pathological heparan sulphate in MPSIIIB mice treated with
genistein aglycone for 9 months. The fact that WT mice do not
show a reduction in brain substrate and the lack of any obvious
Genistein Treatment for MPSIII
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weakly inhibits tyrosine kinases and this is borne out by chronic
studies in the rat and dog suggesting low oral toxicity [8,9].
We did see liver GAG reductions in WT mice treated with
genistein which could reflect higher bioavailability in the liver
[10], coupled with the high metabolic activity of this organ. We
Figure 1. Primary storage substrates are reduced in brains of MPSIIIB mice after genistein treatment. (A) 11 month old MPSIIIB and WT,
male and female mice with and without long-term genistein treatment were sacrificed and 30 mm coronal sections (numbered 1–4) were cut from
each mouse at positions 0.26, 20.46, 21.18 and 21.94 relative to bregma. For cerebral cortex (hatched), two low power fields of view for each
section (boxed) were quantified or positive cells counted (8 fields total), whilst for hippocampus (spots), two low power fields from sections 3–4
(boxed) were quantified (4 fields total). All sections were stained together and blinded to ensure consistency. (B) Representative Lysosomal
Associated Membrane Protein (LAMP2) staining of cerebral cortex of 11 month old MPSIIIB and WT, male and female mice with and without long-
term genistein treatment. This indicates the size of the lysosomal compartment and hence stored material in cells in layers II/III-V/VI of the cerebral
cortex. The images correspond to section 2 shown in Figure 1A. Bar =100 mm. (C) Quantification of mean LAMP2 staining in cerebral cortex is
expressed as a percentage of staining in untreated MPSIIIB mice. (D) Quantification of mean LAMP2 staining of hippocampus. (E) Mean weight of
pathological heparan sulphate in the brain per mg protein, measured using the SensiPro assay. (F) High power view of cerebral cortex layer V - box
from (B). Bar =100 mm. (G) Quantification of mean LAMP2 staining of 2 fields of view from 3 liver sections (6 fields total) is expressed as a percentage
of staining in untreated MPSIIIB mice. (H) Mean weight of total glycosaminoglycans in the liver per mg DNA, measured using the Blyscan assay. For all
graphs genders were pooled, thus n=12 mice per group, error bars represent SEM, p values are for Tukey’s multiple comparisons test.
doi:10.1371/journal.pone.0014192.g001
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previously [13], with male mice storing more GAGs than females.
Genistein still significantly reduced storage in male and female
MPSIIIB mice. No gender or gender*genotype effects were seen in
the brain. Gender specific differences in GAG storage have not
been reported to our knowledge in patients with MPSIIIB and
may just reflect metabolic gender differences in inbred murine
strains.
Our observation that genistein was able to reduce the number of
microglial and astrocytic cells in MPSIIIB mice could have a dual
explanation. Genistein has been reported to reduce LPS induced
inflammatory cytokine production [14], and to inhibit microglial
Figure 2. Neuroinflammatory markers are reduced in brains of MPSIIIB mice after genistein treatment. (A) Representative Glial Fibrillary
Associated Protein (GFAP) staining of astrocytes (brown) in the cerebral cortex of 11 month old MPSIIIB and WT mice with and without long-term
genistein treatment. Sections have been counterstained with haematoxylin to highlight nuclei (blue). The images correspond to section 2 shown in
Figure 1A. Boxed areas are enlarged to show individual astrocyte cell bodies. Bar =100 mm for low power images and 50 mm for enlargements. (B)
The mean number of GFAP positive cells in the cerebral cortex per low power field of view were counted as described in Figure 1. (C) Representative
Isolectin B4 staining of microglial cells (brown) in the cerebral cortex. Sections have been counterstained with haematoxylin to highlight nuclei (blue).
The images correspond to section 2 shown in Figure 1A. Boxed areas are enlarged to show individual microglial cells. Bar =100 mm for low power
images and 50 mm for enlargements. (D) The mean number of Isolectin B4 positive cells in the cerebral cortex per low power field of view were
counted. For all graphs genders were pooled, thus n=12 mice per group, error bars represent SEM, p values are for Tukey’s multiple comparisons
test.
doi:10.1371/journal.pone.0014192.g002
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genistein in direct modulation of neuroinflammation from that of
reduced heparan sulphate storage, as reduction of heparan
sulphate oligosaccharides ameliorates inflammation, although the
converse may not be true [25]. Despite this apparent disconnect,
further investigation of the role of genistein in neuroinflammation
in other neurodegenerative diseases is warranted, since anti-
inflammatories have been shown to reduce microglial cells in
mouse models of Alzheimer disease [26,27] and reduce neuroin-
flammation and prolong life in models of Sandhoff disease [28].
Thus although a reduction in inflammation is unlikely to reduce
primary storage, it may help to improve behavioural manifesta-
tions of disease.
There was some evidence to suggest that genistein was also able
to change other downstream neuropathological events. Although it
was unclear if genistein was able to mediate changes in minor
monosialogangliosides, the data was more clear cut for improve-
ments in synaptic organisation as shown by VAMP2 staining [16].
This is unlikely to reflect a gain in function, instead it is more likely
that genistein is able to delay loss of synaptic transmission, which
would be important if this effect can be replicated in other
neurodegenerative diseases.
Finally, behaviour of MPSIIIB mice was fully corrected to WT
levels by genistein treatment. The hyperactive and increased
exploratory locomotor behaviour of MPSIIIB mice is similar to
that of MPSIIIB patients and is consistent with changes reported
previously by us and others [16,23]. We found the 60 minute open
field test to be an equally good measure of abnormal locomotor
activity in these mice as our circadian locomotor test, with the
advantage of being much shorter [16,23]. Interestingly, the
duration spent in the centre of the cage was virtually unchanged
in MPSIIIB or WT mice in our hands (not shown) suggesting a
normal prey response to danger in these mice. This is in contrast
to decreased responses to danger in MPSIIIB mice observed in the
elevated plus maze [23], although the small size of our arenas
could have reduced these responses [29] and may explain why we
did not observe these differences. Males also showed reduced
responses compared to females in several of these locomotor tests.
Figure 3. Some improvements were seen in secondary metabolite storage and markers of synaptic transmission in brains of
MPSIIIB mice after genistein treatment. (A) Representative GM2 ganglioside staining in the cerebral cortex of 11 month old MPSIIIB mice with
and without long-term genistein treatment at low (layers II/III-V/VI) and high power (layer V). The images correspond to section 2 shown in Figure 1A.
Bar =100 mm. WT mice have no GM2 staining in the cortex and are not shown. (B) Quantification of mean GM2 staining of cerebral cortex in arbitrary
units. (C) Chromatographic profiles of total gangliosides from the fourth brain hemicoronal fifth (rostral to caudal). Each lane represents 3mg wet
weight of pooled sections from 4 mice. (D) Representative Vesicle Associated Membrane Protein (VAMP2) staining in the cerebral cortex. VAMP2 is a
synaptic vesicle marker required for effective synaptic transmission. The images correspond to section 2 shown in Figure 1A. Bar =100 mm. (E)
Quantification of mean VAMP2 staining of cerebral cortex in arbitrary units. For all graphs genders were pooled, thus n=12 mice per group, error
bars represent SEM, p values are for Tukey’s multiple comparisons test.
doi:10.1371/journal.pone.0014192.g003
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shown), often leading to hydronephrosis or uremia, which may
reflect autonomic control of urinary sphincter function or more
likely, blockage of the urinary tract [30]. This manifestation of
disease appears earlier in males than females, leads to gait
abnormalities and is often the humane endpoint. This may limit
male MPSIIIB mice in their locomotor activity giving the illusion
of less pathology in these tasks. Given that urinary retention is not
reported in humans with MPSIIIB, extended studies of lifespan in
MPSIIIB mice where urinary retention is the primary endpoint
have limited value in indicating improvements in neuropathology.
Genistein is widely available as a food supplement, occurring
naturally within soy foods predominantly in a glycoside form
(genistin) [31] and can also be synthesised or purified in its
aglycone form. A concentrated form of soy extract has been used
in clinical trial for patients with MPSIIIA and IIIB at 5–10 mg/
kg/day, doses that we would predict from our previous data [13]
would not be effective in the brain but may clear peripheral
storage. This open label study was not designed to study
neurological outcomes but did show small reductions in urinary
GAGs [12]. Although genistein has been widely tested for safety
and efficacy at reducing incidence of various forms of cancer [32]
its only approved clinical indication to our knowledge is for
osteopenia using relatively low doses [33]. Our use of genistein
aglycone, which is reported to be less susceptible to degradation
by gut flora than genistin [31], has high plasma bioavailability
[34] and delivery of high doses to ensure sufficient blood brain
barrier diffusion [10] may explain why our approach was
effective.
In conclusion, genistein aglycone significantly reduces brain
lysosomal storage, and neuroinflammation, delays synaptic loss
and corrects behaviour in mice with MPSIIIB. Due to its
multimodal actions, genistein may prove applicable in delaying
clinical onset of disease and neuroinflammation in MPSIIIB and
similar neurodegenerative metabolic diseases.
Materials and Methods
Mouse maintenance and drug administration
Animal procedures were ethically approved and carried out in
accordance with UK Home Office regulations under project
licence PPL 40/3056. The MPSIIIB knock-out mouse [35] was
maintained as a heterozygote line on an inbred C57BL/6J
background at the University of Manchester, UK as previously
described [16]. Eight week old male and female MPSIIIB and WT
mice (n=6–7 per group) received a soy free diet (2014 Teklad
Global Rodent Diet, Harlan, England) or the same diet containing
160 mg/kg/day genistein aglycone (Pharmaceutical Research
Institute, Warsaw, Poland). 2 mice from the MPSIIIB untreated
and 2 from the MPSIIIB treated groups were found dead at 9–10
months of age and excluded from biochemical or histological
analysis.
Figure 4. Genistein treatment corrects behavioural abnormalities seen in MPSIIIB mice. (A) 8 month old MPSIIIB and WT, male and female
mice with and without long-term genistein treatment were monitored in the open field test of locomotor and exploratory activity for 60 minutes. The
arena was divided into 12 squares and the frequency of entry (and total duration- not shown) to the central 4 squares measured to determine
responses to danger and thigmotaxis. (B) The average speed in the central area and (C) side squares was also measured, as was (D) total distance
travelled, to give an indication of abnormal locomotor activity. (E) Rapid exploratory behaviour was measured by frequency and (F) duration of speed
more than 90 mm/s. (G) The number of times and (H) the duration of time spent immobile was also measured as speed under 0.05 mm/s. (I) Latency
to cross or fall from a hanging bar is a measure of locomotor activity with some element of cognitive function due to a training period and was tested
at 10 months of age. Significant gender*genotype effects were seen in centre and side speed, distance travelled, frequency of speed over 90 mm/s,
immobility frequency and duration reflecting greater pathological effect in female MPSIIIB mice. For all graphs genders were pooled, thus n=12–14
mice per group, error bars represent SEM, p values are for Tukey’s multiple comparisons test.
doi:10.1371/journal.pone.0014192.g004
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All animals had access ad libitum to food and water. Behavioural
testing was performed between 8:00 and 10:00 A.M. on naı ¨ve
mice, standardizing as many environmental parameters as possible
[29]. The tester was blinded to genotype.
Open field test
8 month old mice were placed in the centre of one of 4 opaque
arenas (48063756210 mm) and monitored for 60 minutes by
digital camera. Arenas were cleaned between sessions. Videos
were analyzed and scored in an unbiased fashion using TopScan
Suite (Clever Sys. Inc, Virginia, USA) and random videos were
checked for consistency of automated scoring. Locomotor
measures included total distance travelled, duration and frequency
of immobility (speed less than 0.05 mm/s), duration and frequency
of rapid exploration (speed over 60 mm/s and 90 mm/s). The
arena was divided into 12 squares and frequency and duration of
crossover to or from the 4 central squares was used to measure
locomotor activity and response to danger. Frequency and
duration of rearing was not found to be consistent using Topscan
suite.
Hanging bar test
Mice were tested individually with randomization. The test was
modified from [24]. Briefly, a metal bar 25 cm long was located
horizontally between 2 wooden columns. The animal was held by
the tail and allowed to grasp the centre of the bar with forepaws
only before release. Latency to cross or fall was scored as described
[24]. Each animal had 3 training trials with a 10 min rest before
the final scored trial. Results are presented as an average of 3
trials, and the test was performed at 10 months of age.
Tissue preparation
Mice were sacrificed by dislocation of the cervical vertebrae.
Brains were divided into two hemispheres. One hemisphere was
fixed (4% paraformaldehyde/PBS) for 24 hours followed by
cryoprotection with 30%sucrose/PBS/2mMgCl2 for 48 hours at
4uC and stored at 280uC for histological analysis. The entire fixed
hemisphere was cut into coronal sections (30 mm) using a sledge
microtome (Hyrax S30, Zeiss, Germany) and each section stored
in sequential wells of a 96 well plate. Staining was performed on
free-floating sections before mounting on superfrost slides (Fisher
Scientific, USA). The other hemisphere was divided into
hemicoronal fifths, snap frozen, and stored at 280uC for
biochemistry. For liver, half a lobe was fixed (4% paraformalde-
hyde/PBS) and embedded in paraffin for histology. 6 mm-thick
sections were mounted on superfrost slides before staining. The
other half was snap frozen for biochemistry.
Immunohistochemistry
For staining to be quantifiable and comparable, 4 brain sections
were taken from positions 0.26, 20.46 21.18 and 21.94 mm
relative to bregma [36], from every mouse (n=6–7), in all 8
groups and all 192 sections stained concurrently for each marker
and developed for exactly the same period of time. Each marker
used the next adjacent set of comparative sections from positions
0.26, 20.46 21.18 and 21.94 mm relative to bregma. For brains,
LAMP2, GFAP, VAMP2, and Isolectin B4 staining was performed
as previously described [13,16]. The anti-GM2 antibody (a gift
from Dr Kostantin Dobrenis and Prof Walkley) was diluted 1/40
and the staining was performed as previously described [20].
Sections were visualised with diaminobenzidine (DAB substrate
kit, Vector Labs Inc.). For quantification analysis, nickel was
added to the DAB substrate to obtain black staining for easier
quantification. Isolectin B4 and GFAP sections were counter-
stained with Mayer’s haematoxylin. Liver sections were stained for
LAMP2 as previously described [13].
Image analysis
Two non-overlapping low power (x20 objective) fields of view
were digitally photographed from each of the 4 sections, as shown
in Figure 1A, using an Axioscope light microscope and Axiocam
color CCD with Axiovision software (Figure 1A).
The first field of view was taken with the left edge of the field of
view in line with the apex of the cingulum and at a right angle to
the fibres of the corpus callosum and positioned so that cerebral
cortical laminas II/III-V/VI were photographed. The second
non-overlapping field of view was taken adjacent to the first field of
view covering cerebral cortical laminas II/III-V/VI. This ensured
that the same fields of view were taken for each section for each
mouse (total 8 non-overlapping fields per mouse [n=6–7/group]).
For the hippocampus, two non-overlapping low power (x20
objective) fields of view were digitally photographed from the third
and fourth sections (relative to Bregma 21.18 and 1.94) with the
first field of view covering the CA1 region and the second covering
the CA2 and CA3 regions of the hippocampus as shown in
Figure 1A (total of 4 non-overlapping fields per mouse [n=6–7/
group]). Identical exposure settings were used for each stain and all
photographs taken in one session. Images were transformed to
eight bits of grey resolution and stored in TIFF format. To
quantify LAMP2, VAMP2, GM2 staining, Image J software (NIH,
USA) was used. Each entire unmanipulated field of view was
blinded and quantified for the stain, whilst an unstained area was
used to determine (and subtract) background staining for each
section. An average of the levels of optical density for each section
and each mouse was calculated. These were then averaged to give
a group mean for cerebral cortex or hippocampus for each mouse.
To quantify Isolectin B4 or GFAP staining, the number of positive
cells per non-overlapping cortical field (as described above) was
counted and all 8 fields averaged for each mouse. We have also
included examples of full sized high quality images of GFAP
staining that were used for counting astrocytes as supplementary
data to show that individual astrocytes are easily distinguishable at
this magnification (See Figures S1, S2, S3, and S4). These images
correspond to the first field of view on section 2 as shown in
Figure 1A, and to the images presented in Figure 2A.
Biochemical assays
All samples were analyzed in blinded fashion. Liver samples
were prepared as previously described. Total sulphated glycos-
aminoglycans in livers were measured using the Blyscan kit
(Biocolor Ltd.,UK), standardized against DNA using PicoGreen H
dsDNA Kit (Invitrogen Ltd, UK) as previously described [13]. The
final values were the mean of three tissue samples. High
performance liquid chromatography (HPLC) was used to quantify
the presence of pathological GAGs which have accumulated due
to reduced enzyme activity in the brain from the second
hemicoronal fifth (rostral to caudal) (SensiPro assay, Zacharon
Pharmaceuticals Inc., data on file). Tissue GAG was extracted as
previously described [37]. Samples were prepared by normalizing
each to equivalent volumes using phosphate buffered saline
followed by purification using reagents to extract impurities and
isolate pathogenic GAG (pGAG). The pGAG were tagged with
fluorescent dye, analyzed by HPLC [37] and this was standardized
against total protein in each sample (Bradford assay). Tissue lipid
extraction, isolation and quantitative densitometric studies of
Genistein Treatment for MPSIII
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performed as previously described [23,25].
Statistics
For statistical analysis, extreme outliers in biochemical and
immunohistochemical data were formally removed using the
boxplot tool in SPSS (Those more than 3x the interquartile range
outside of the end of the interquartile box). None were removed
from behavioural data due to the possibility of excluding erratic
phenotypes. Data were analysed using 3 way ANOVA for gender
(Male/Female), genotype (MPSIIIB/WT), drug (Untreated/Gen-
istein) and Tukey’s multiple comparisons test used to determine
differences between groups using JMP software (SAS Ltd, UK).
Supporting Information
Figure S1 WT control GFAP stain x20.tif. The full sized TIFF
image of GFAP (brown) stained cerebral cortex from an untreated
11 month old WT mouse. This image corresponds to the first field
of view on section 2 as shown in Figure 1A, to the image presented
in Figure 2A and was used to count the number of GFAP-positive
cells. The section was counterstained with Mayer’s haematoxylin
(blue) to highlight the nuclei of cells.
Found at: doi:10.1371/journal.pone.0014192.s001 (36.15 MB
TIF)
Figure S2 MPS IIIB control GFAP stain x20.tif. The full sized
TIFF image of GFAP (brown) stained cerebral cortex from an
untreated 11 month old MPSIIIB mouse. This image corresponds
to the first field of view on section 2 as shown in Figure 1A, to the
image presented in Figure 2A and was used to count the number
of GFAP-positive cells. The section was counterstained with
Mayer’s haematoxylin (blue) to highlight the nuclei of cells.
Found at: doi:10.1371/journal.pone.0014192.s002 (36.15 MB
TIF)
Figure S3 WT genistein treated GFAP stain x20.tif. The full
sized TIFF image of GFAP (brown) stained cerebral cortex from a
genistein treated 11 month old WT mouse. This image
corresponds to the first field of view on section 2 as shown in
Figure 1A, to the image presented in Figure 2A and was used to
count the number of GFAP-positive cells. The section was
counterstained with Mayer’s haematoxylin (blue) to highlight the
nuclei of cells.
Found at: doi:10.1371/journal.pone.0014192.s003 (36.15 MB
TIF)
Figure S4 MPS IIIB genistein treated GFAP stain x20.tif. The
full sized TIFF image of GFAP (brown) stained cerebral cortex
from a genistein treated 11 month old MPSIIIB mouse. This
image corresponds to the first field of view on section 2 as shown in
Figure 1A, to the image presented in Figure 2A and was used to
count the number of GFAP-positive cells. The section was
counterstained with Mayer’s haematoxylin (blue) to highlight the
nuclei of cells.
Found at: doi:10.1371/journal.pone.0014192.s004 (36.15 MB
TIF)
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